← All countries · Americas
90.5%
MCV1
2025 · Administrative (country-reported)
85.2%
DTP3
2024 · Administrative (country-reported)
90.1%
HepB3
2025 · Administrative (country-reported)
0
Measles cases
2025 reported
2
Pertussis (whooping cough) cases
2025 reported
Two kinds of number live on this page. Coverage is the share of the target cohort vaccinated, as estimated by WHO and UNICEF each July from the country's reports, surveys and other evidence, shown beside what the country itself reported. Reported cases are what the national surveillance system sent to WHO; they are a floor, not a count of infections. Every row carries a grade; hover or focus it for the reason, or read how grades are assigned.
Vaccination coverage
| Vaccine | Latest estimate | Country-reported | Trend since 2000 | Data quality |
|---|---|---|---|---|
| BCGTuberculosis vaccine at birth | —% · Administrative (country-reported) | — | too few points | no data |
| DTP1First dose of diphtheria-tetanus-pertussis | 98.5%2024 · Administrative (country-reported) | 98.5% | too few points | D · poor |
| DTP3Third dose of diphtheria-tetanus-pertussis (the WHO benchmark of a working programme) | 85.2%2024 · Administrative (country-reported) | 85.2% | too few points | D · poor |
| IPV1First dose of inactivated polio vaccine | —% · Administrative (country-reported) | — | too few points | no data |
| IPV completeInactivated polio vaccine, complete primary series | —% · Administrative (country-reported) | — | too few points | no data |
| MCV1First dose of measles-containing vaccine | 90.5%2025 · Administrative (country-reported) | 90.5% | D · poor | |
| MCV2Second dose of measles-containing vaccine | 78.2%2025 · Administrative (country-reported) | 78.2% | D · poor | |
| RCV1First dose of rubella-containing vaccine | 90.5%2025 · Administrative (country-reported) | 90.5% | D · poor | |
| HepB3Third dose of hepatitis B vaccine | 90.1%2025 · Administrative (country-reported) | 90.1% | D · poor | |
| HepB birthHepatitis B birth dose within 24 hours | —% · Administrative (country-reported) | — | too few points | no data |
| Hib3Third dose of Haemophilus influenzae type b vaccine | 90.1%2025 · Administrative (country-reported) | 90.1% | D · poor | |
| PCV1Pneumococcal conjugate vaccine, first dose | 79.7%2024 · Administrative (country-reported) | 79.7% | too few points | D · poor |
| PCV completePneumococcal conjugate vaccine, final dose of the schedule | 90.1%2025 · Administrative (country-reported) | 90.1% | D · poor | |
| RotaCRotavirus vaccine, complete series | —% · Administrative (country-reported) | — | too few points | no data |
| Yellow feverYellow fever vaccine (countries at risk) | —% · Administrative (country-reported) | — | too few points | no data |
| TCVTyphoid conjugate vaccine | —% · Administrative (country-reported) | — | too few points | no data |
| PABProtection at birth against neonatal tetanus (maternal tetanus doses) | —% · Administrative (country-reported) | — | too few points | no data |
Reported vaccine-preventable disease
| Disease | Reported cases | Incidence rate | Trend since 2000 | Data quality |
|---|---|---|---|---|
| Measles all countries · vaccine evidence | 02025 | —per 1,000,000 total population | D · poor | |
| Rubella all countries · vaccine evidence | 02025 | —per 1,000,000 total population | D · poor | |
| Congenital rubella syndrome all countries · vaccine evidence | 02025 | —per 10,000 live births | D · poor | |
| Mumps all countries · vaccine evidence | 02025 | —per 1,000,000 total population | D · poor | |
| Pertussis (whooping cough) all countries · vaccine evidence | 22025 | —per 1,000,000 total population | D · poor | |
| Diphtheria all countries · vaccine evidence | 02025 | —per 1,000,000 total population | D · poor | |
| Tetanus (total) all countries · vaccine evidence | 02025 | —per 1,000,000 total population | D · poor | |
| Neonatal tetanus all countries · vaccine evidence | 02025 | —per 1,000 live births | D · poor | |
| Polio (paralytic) all countries · vaccine evidence | 02025 | —per 1,000,000 <15 population | D · poor | |
| Yellow fever all countries · vaccine evidence | 02025 | —per 1,000,000 total population | D · poor | |
| Invasive meningococcal disease all countries · vaccine evidence | 02025 | —per 1,000,000 total population | D · poor | |
| Typhoid all countries · vaccine evidence | 02025 | —per 1,000,000 total population | D · poor |
National schedule (latest WHO listing)
Show the schedule (24 rows)
| Vaccine | Dose | Age | Target group | Comment |
|---|---|---|---|---|
| COVID19COVID-19 vaccine | 1 | Adults | All older adults | |
| DTAPHIBHEPBIPVDTaP-Hib-HepB-IPV (acellular) vaccine | 1 | M2 | General/routine | |
| DTAPHIBHEPBIPVDTaP-Hib-HepB-IPV (acellular) vaccine | 2 | M3 | General/routine | |
| DTAPHIBHEPBIPVDTaP-Hib-HepB-IPV (acellular) vaccine | 3 | M5 | General/routine | |
| DTAPHIBHEPBIPVDTaP-Hib-HepB-IPV (acellular) vaccine | 4 | M12 | General/routine | |
| DTAPIPVDTaP-IPV (acellular) vaccine | 5 | Y5 | General/routine | |
| DTIPVDT-IPV (Diphtheria and tetanus toxoid and IPV) vaccine | 6 | Y14 | General/routine | |
| HPV2HPV-2 (Human papillomavirus 2-valent) vaccine | 1 | Y9 | HPV administered to females and males | males and females |
| HPV2HPV-2 (Human papillomavirus 2-valent) vaccine | 2 | Y9.5 | HPV administered to females and males | males and females |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | >=Y60 | Adults | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Health workers | Health and care workers | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Pregnant women | Pregnant women | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Risk group(s) | Adults with chronic conditions, residents living in long-term care facilities | |
| INFLUENZA_PEDIATRICPediatric seasonal influenza vaccine | 1 | General/routine | Children | |
| INFLUENZA_PEDIATRICPediatric seasonal influenza vaccine | 1 | Risk group(s) | Children with chronic conditions | |
| MEN_ACYW_135PSMeningococcal ACYW polysaccharide vaccine | 1 | M14 | General/routine | |
| MEN_ACYW_135PSMeningococcal ACYW polysaccharide vaccine | 2 | Y14 | General/routine | |
| MMRVMMRV (Measles, mumps, rubella and varicella) vaccine | 1 | M14 | General/routine | |
| MMRVMMRV (Measles, mumps, rubella and varicella) vaccine | 2 | M18 | General/routine | |
| PCV_15_VALENTPCV-15 (Pneumococcal conjugate vaccine 15-valent) vaccine | 1 | M3 | General/routine | |
| PCV_15_VALENTPCV-15 (Pneumococcal conjugate vaccine 15-valent) vaccine | 2 | M5 | General/routine | |
| PCV_15_VALENTPCV-15 (Pneumococcal conjugate vaccine 15-valent) vaccine | 3 | M12 | General/routine | |
| ROTAVIRUS_1RV-1 (Rotavirus 1-valent) vaccine | 1 | M2 | General/routine | |
| ROTAVIRUS_1RV-1 (Rotavirus 1-valent) vaccine | 2 | M3 | General/routine |
Compare schedules across 31 countries on the schedule hub.
Data and sources
- Download this country's data (JSON): every year, every antigen and disease, with the grade reasons.
- Coverage: WHO/UNICEF Estimates of National Immunization Coverage (WUENIC) and country-reported administrative/official coverage, from the WHO Immunization Data Portal export downloaded 21 October 2026.
- Reported cases and incidence: WHO/UNICEF Joint Reporting Form, same export. Incidence denominators are stated per row.
- Schedule: WHO vaccine-schedule export, latest listing year.